Accolade, Inc.

Informe acción NasdaqGS:ACCD

Capitalización de mercado: US$723.8m

Salud financiera de hoja de balance de Accolade

Salud financiera controles de criterios 5/6

Accolade tiene un patrimonio de los accionistas total de $434.7M y una deuda total de $208.2M, lo que sitúa su ratio deuda-patrimonio en 47.9%. Sus activos y pasivos totales son $785.5M y $350.8M respectivamente.

Información clave

47.9%

Ratio deuda-patrimonio

US$208.18m

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$230.02m
PatrimonioUS$434.72m
Total pasivoUS$350.75m
Activos totalesUS$785.47m

Actualizaciones recientes sobre salud financiera

Here's Why We're Not Too Worried About Accolade's (NASDAQ:ACCD) Cash Burn Situation

Mar 19
Here's Why We're Not Too Worried About Accolade's (NASDAQ:ACCD) Cash Burn Situation

Recent updates

Accolade: Staying Bullish On Favorable Developments

Apr 05

Why We're Not Concerned About Accolade, Inc.'s (NASDAQ:ACCD) Share Price

Feb 17
Why We're Not Concerned About Accolade, Inc.'s (NASDAQ:ACCD) Share Price

Accolade: Remain Confident That FY25 Guided Growth Is Achievable

Jan 17

Accolade: Turning Bullish After Beat-And-Raise Quarter (Rating Upgrade)

Jan 11

Why Investors Shouldn't Be Surprised By Accolade, Inc.'s (NASDAQ:ACCD) 27% Share Price Surge

Jun 13
Why Investors Shouldn't Be Surprised By Accolade, Inc.'s (NASDAQ:ACCD) 27% Share Price Surge

Is There Now An Opportunity In Accolade, Inc. (NASDAQ:ACCD)?

May 02
Is There Now An Opportunity In Accolade, Inc. (NASDAQ:ACCD)?

An Intrinsic Calculation For Accolade, Inc. (NASDAQ:ACCD) Suggests It's 28% Undervalued

Feb 05
An Intrinsic Calculation For Accolade, Inc. (NASDAQ:ACCD) Suggests It's 28% Undervalued

Accolade: Inching Closer To Profitability

Oct 17

Accolade Q2 2023 Earnings Preview

Oct 05

Accolade: Fair And Reasonably Priced, But Needs More Time

Aug 09

Accolade Q1 2023 Earnings Preview

Jun 29

Accolade: Little Recent Applause

Mar 28

Accolade Impresses With Revenue Growth But Faces Operating Losses

Dec 16

Accolade: I May Add To My Position

Oct 18

Accolade, Inc. (NASDAQ:ACCD) Just Reported And Analysts Have Been Lifting Their Price Targets

Jul 11
Accolade, Inc. (NASDAQ:ACCD) Just Reported And Analysts Have Been Lifting Their Price Targets

Accolade, Inc. 2021 Q4 - Results - Earnings Call Presentation

May 06

Here's Why We're Not Too Worried About Accolade's (NASDAQ:ACCD) Cash Burn Situation

Mar 19
Here's Why We're Not Too Worried About Accolade's (NASDAQ:ACCD) Cash Burn Situation

Is Accolade, Inc. (NASDAQ:ACCD) Popular Amongst Institutions?

Jan 15
Is Accolade, Inc. (NASDAQ:ACCD) Popular Amongst Institutions?

Accolade is up 7% on acquisition of 2nd.MD

Jan 14

Accolade Inc.: Bullish Outlook As Its HealthTech Platform Helps Companies Save

Jan 12

Accolade, Inc. 2021 Q3 - Results - Earnings Call Presentation

Jan 11

Accolade Q3 2021 Earnings Preview

Jan 06

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($272.1M) de ACCD superan a sus pasivos a corto plazo ($115.7M).

Pasivo a largo plazo: Los activos a corto plazo de ACCD ($272.1M) superan a sus pasivos a largo plazo ($235.1M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: ACCD tiene más efectivo que su deuda total.

Reducción de la deuda: ACCD tenía patrimonio neto negativo hace 5 años, pero ahora es positivo y, por lo tanto, ha mejorado.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ACCD tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si ACCD tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.


Descubre empresas con salud financiera

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target